In vitro assessment of mesenchymal stem cells immunosuppressive potential in multiple sclerosis patients

Immunology Letters

Volumn 149, Issue 1-2, 2013, Pages 9-18

  Zafranskaya, Marina M ^a   Nizheharodova, Darya B ^a   Yurkevich, Mariya Yu ^a   Lamouskaya, Natallia V ^a   Motuzova, Yana M ^b,c   Bagatka, Svetlana S ^a   Ivanchik, Halina I ^a   Fedulov, Alexander S ^b,c  

^a BELARUSIAN MEDICAL ACADEMY OF POSTGRADUATE EDUCATION   (Belarus)

^b BELARUSIAN STATE MEDICAL UNIVERSITY   (Belarus)

^c Hospital No 9   (Belarus)

Author keywords

Immunosuppression; Mesenchymal stem cells; Multiple sclerosis

Indexed keywords

GAMMA INTERFERON RECEPTOR 1; MITOGENIC AGENT; MYELIN;

ADULT; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CLINICAL ARTICLE; COCULTURE; CONTROLLED STUDY; CORRELATION ANALYSIS; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; LYMPHOCYTE; LYMPHOCYTE PROLIFERATION; MALE; MEMORY T LYMPHOCYTE; MESENCHYMAL STEM CELL; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ADULT; CELL PROLIFERATION; CELLS, CULTURED; FEMALE; GENE EXPRESSION REGULATION; HUMANS; IMMUNE TOLERANCE; MALE; MESENCHYMAL STROMAL CELLS; MIDDLE AGED; MULTIPLE SCLEROSIS; RECEPTORS, INTERFERON; T-LYMPHOCYTES;

EID: 84872406089     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2012.10.010     Document Type: Article

References (73)

1. Caplan A.I. Mesenchymal stem cells. J Orthop Res 1991, 9(5):641-650.
2. Krampera M., Franchini M., Pizzolo G., Aprili G. Mesenchymal stem cells: from biology to clinical use. Blood Transfus 2007, 5:120-129.
3. Newman R.E., Yoo D., LeRoux M.A., Danilkovitch-Miagkova A. Treatment of inflammatory diseases with mesenchymal stem cells. Inflamm Allergy Drug Targets 2009, 8(2):110-123.
4. Uccelli A., Moretta L., Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol 2008, 8(9):726-736.
5. Steinman L. Immunotherapy of multiple sclerosis: the end of the beginning. Curr Opin Immunol 2001, 13(5):597-600.
6. Singer N.G., Caplan A.I. Mesenchymal stem cells: mechanisms of inflammation. Annu Rev Pathol Mech Dis 2011, 6:457-478.
7. Keating A. How do mesenchymal stromal cells suppress T cells?. Cell Stem Cell 2008, 2(2):106-108.
8. Tyndall A., Uccelli A. Multipotent mesenchymal stromal cells for autoimmune disease: teaching new dogs old tricks. Bone Marrow Transplant 2009, 43(11):821-828.
9. Sajic M., Hunt D.P., Lee W., Compston D.A., Schweimer J.V., Gregson N.A., et al. Mesenchymal stem cells lack efficacy in the treatment of experimental autoimmune neuritis despite in vitro inhibition of T-cell proliferation. PLoS One 2012, 7(2):e30708.
10. Mazzanti B., Aldinucci A., Biagioli T., Barilaro A., Urbani S., Dal Pozzo S., et al. Differences in mesenchymal stem cell cytokine profiles between MS patients and healthy donors: implication for assessment of disease activity and treatment. J Neuroimmunol 2008, 199(1-2):142-150.
11. Hafler D.A., Slavik J.M., Anderson D.E., O'Connor K.C., de Jager P., Baecher-Allan C. Multiple sclerosis. Immunol Rev 2005, 204:208-231.
12. Sospedra M., Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 2005, 23:683-747.
13. Gold R., Linington C., Lassmann H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 2006, 129(8):1953-1971.
14. Crawford M.P., Yan S.X., Ortega S.B., Mehta R.S., Hewitt R.E., Price D.A., et al. High prevalence of autoreactive, neuroantigen-specific CD8+ T cells in multiple sclerosis revealed by novel flow cytometric assay. Blood 2004, 103(11):4222-4231.
15. Goverman J. Autoimmune T cell responses in the central nervous system. Nat Rev Immunol 2009, 9(6):393-407.
16. Okuda Y., Okuda M., Apatoff B.R., Posnett D.N. The activation of memory CD4+ T cells and CD8+ T cells in patients with multiple sclerosis. J Neurol Sci 2005, 235:11-17.
17. Ratts R.B., Karandikar N.J., Hussain R.Z., Choy J., Northrop S.C., Lovett-Racke A.E., et al. Phenotypic characterization of autoreactive T cells in multiple sclerosis. J Neuroimmunol 2006, 178(1-2):100-110.
18. Sallusto F., Geginat J., Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 2004, 22:745-763.
19. Hohlfeld R., Wekerle H. Autoimmune concepts of multiple sclerosis as a basic for selective immunotherapy: from pipe dreams to (therapeutic) pipelines. Proc Natl Acad Sci U S A 2004, 101(2):14599-14606.
20. Zappia E., Casazza S., Pedemonte E., Benvenuto F., Bonanni I., Gerdoni E., et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 2005, 106(5):1755-1761.
21. Río J., Comabella M., Montalban X. Predicting responders to therapies for multiple sclerosis. Nat Rev Neurol 2009, 5(10):553-560.
22. Novak J.C., Lovett-Racke A.E., Racke M.K. Monoclonal antibody therapies and neurologic disorders. Arch Neurol 2008, 65(9):1162-1165.
23. Racke M.K., Lovett-Racke A.E. Glatiramer acetate treatment of multiple sclerosis: an immunological perspective. J Immunol 2011, 186(4):1887-1890.
24. Vosoughi R., Freedman M.S. Therapy of MS. Clin Neurol Neurosurg 2010, 112(5):365-385.
25. Karussis D., Kassis I., Kurkalli B.G., Slavin S. Immunomodulation and neuroprotection with mesenchymal bone marrow stem cells (MSCs): a proposed treatment for multiple sclerosis and other neuroimmunological/neurodegenerative diseases. J Neurol Sci 2008, 265(1-2):131-135.
26. Kassis I., Grigoriadis N., Gowda-Kurkalli B., Mizrachi-Kol R., Ben-Hur T., Slavin S., Abramsky O., et al. Neuroprotection and immunomodulation with mesenchymal stem cells in chronic experimental autoimmune encephalomyelitis. Arch Neurol 2008, 65(6):753-761.
27. Krampera M., Pasini A., Pizzolo G., Cosmi L., Romagnani S., Annunziato F. Regenerative and immunomodulatory potential of mesenchymal stem cells. Curr Opin Pharmacol 2006, 6(4):435-441.
28. Le Blanc K. Immunomodulatory effects of fetal and adult mesenchymal stem cells. Cytotherapy 2003, 5(6):485-489.
29. Uccelli A., Laroni A., Freedman M.S. Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases. Lancet Neurol 2011, 10(7):649-656.
30. Aggarwal S., Pittenger M. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005, 105(4):1815-1822.
31. Gieseke F., Schütt B., Viebahn S., Koscielniak E., Friedrich W., Handgretinger R., et al. Human multipotent mesenchymal stromal cells inhibit proliferation of PBMCs independently of IFNgammaR1 signaling and IDO expression. Blood 2007, 110(6):2197-2200.
32. Glennie S., Soeiro I., Dyson P.J., Lam E.W., Dazzi F. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 2005, 105(7):2821-2827.
33. Ren G., Su J., Zhang L., Zhao X., Ling W., L'huillie A., et al. Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression. Stem Cells 2009, 27(8):1954-1962.
34. Nasef A., Ashammakhi N., Fouillard L. Immunomodulatory effect of mesenchymal stromal cells: possible mechanisms. Regen Med 2008, 3(4):531-546.
35. Kode J.A., Mukherjee S., Joglekar M.V., Hardikar A.A. Mesenchymal stem cells: immunobiology and role in immunomodulation and tissue regeneration. Cytotherapy 2009, 11(4):377-391.
36. Connick P., Kolappan M., Patani R., Scott M.A., Crawley C., He X.L., et al. The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments. Trials 2011, 12:62.
37. Karussis D., Karageorgiou C., Vaknin-Dembinsky A., Gowda-Kurkalli B., Gomori J.M., Kassis I., et al. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch Neurol 2010, 67(10):1187-1194.
38. Kurtzke J.F. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983, 33(11):1444-1452.
39. Polman C.H., Reingold S.C., Banwell B., Clanet M., Cohen J.A., Filippi M., et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011, 69(2):292-302.
40. Pittenger M.F., Mackay A.M., Beck S.C., Jaiswal R.K., Douglas R., Mosca J.D., et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284(5411):143-147.
41. Parish Ch., Warren H.S. Use of the intracellular fluorescent dye CFSE to monitor lymphocyte migration and proliferation. Current protocols in immunology 2001, John Wiley & Sons, Inc., New York, Supplement 42.
42. + T-cell reactivity in multiple sclerosis. Immunology 2007, 121(1):29-39.
43. Longbrake E.E., Racke M.K. Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis?. Expert Rev Neurother 2009, 9(3):319-321.
44. Pender M.P., Wolfe N.P. Prevention of autoimmune attack and disease progression in multiple sclerosis: current therapies and future prospects. Intern Med J 2002, 32(11):554-563.
45. Ghannam S., Bouffi C., Djouad F., Jorgensen C., Noël D. Immunosuppression by mesenchymal stem cells: mechanisms and clinical applications. Stem Cell Res Ther 2010, 1(1):2.
46. Abdelrazik H., Spaggiari G.M., Chiossone L., Moretta L. Mesenchymal stem cells expanded in human platelet lysate display a decreased inhibitory capacity on T- and NK-cell proliferation and function. Eur J Immunol 2011, 41(11):3281-3290.
47. Di Nicola M., Carlo-Stella C., Magni M., Milanesi M., Longoni P.D., Matteucci P., et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002, 99(10):3838-3843.
48. Gerdoni E., Gallo B., Casazza S., Musio S., Bonanni I., Pedemonte E., et al. Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis. Ann Neurol 2007, 61(3):219-227.
49. Krampera M., Glennie S., Dyson J., Scott D., Laylor R., Simpson E., et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003, 101(9):3722-3729.
50. Rasmusson I., Ringden O., Sundberg B., Le Blank K. Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. Exp Cell Res 2005, 305(1):33-41.
51. Bartholomew A., Sturgeon C., Siatskas M., Ferrer K., McIntosh K., Patil S., et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002, 30(1):42-48.
52. Bai L., Lennon D.P., Eaton V., Maier K., Caplan A.I., Miller S.D., et al. Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis. Glia 2009, 57(11):1192-1203.
53. Rafei M., Birman E., Forner K., Galipeau J. Allogeneic mesenchymal stem cells for treatment of experimental autoimmune encephalomyelitis. Mol Ther 2009, 17(10):1799-1803.
54. Morando S., Vigo T., Esposito M., Casazza S., Novi G., Principato M.C., et al. The therapeutic effect of mesenchymal stem cell transplantation in experimental autoimmune encephalomyelitis is mediated by peripheral and central mechanisms. Stem Cell Res Ther 2012, 3(1):3.
55. Connick P., Kolappan M. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. Lancet Neurol 2012, 11(2):150-156.
56. Mohajeri M., Farazmand A., Mohyeddin Bonab M., Nikbin B., Minagar A. FOXP3 gene expression in multiple sclerosis patients pre- and post mesenchymal stem cell therapy. Iran J Allergy Asthma Immunol 2011, 10(3):155-161.
57. Rice C.M., Mallam E.A., Whone A.L., Wals P., Brooks D.J., Kane N., et al. Safety and feasibility of autologous bone marrow cellular therapy in relapsing-progressive multiple sclerosis. Clin Pharmacol Ther 2010, 87(6):679-685.
58. Lindert R.B., Haase C.G., Brehm U., Linington C., Wekerle H., Hohlfeld R. Multiple sclerosis. B- and T-cell responses to the extracellular domain of the myelin oligodendrocyte glycoprotein. Brain 1999, 122:2089-2099.
59. Bruno R., Sabater L., Sospedra M., Ferrer-Francesch X., Escudero D., Martínez-Cáceres E., et al. Multiple sclerosis candidate autoantigens except myelin oligodendrocyte glycoprotein are transcribed in human thymus. Eur J Immunol 2002, 32(10):2737-2747.
60. Hellings N., Barée M., Verhoeven C., D'hooghe M.B., Medaer R., Bernard C.C., et al. T-cell reactivity to multiple myelin antigens in multiple sclerosis patients and healthy controls. J Neurosci Res 2001, 63(3):290-302.
61. Koehler N.K., Genain C.P., Giesser B., Hauser S.L. The human T cell response to myelin oligodendrocyte glycoprotein: a multiple sclerosis family-based study. J Immunol 2002, 168(11):5920-5927.
62. Bielekova B., Sung M.H., Kadom N., Simon R., McFarland H., Martin R. Expansion and functional relevance of high-avidity myelin-specific CD4+ T cells in multiple sclerosis. J Immunol 2004, 72:3893-3904.
63. Mallam E., Kemp K., Wilkins A., Rice C., Scolding N. Characterization of in vitro expanded bone marrow-derived mesenchymal stem cells from patients with multiple sclerosis. Mult Scler 2010, 16(8):909-918.
64. Darlington P.J., Boivin M.N., Bar-Or A. Harnessing the therapeutic potential of mesenchymal stem cells in multiple sclerosis. Expert Rev Neurother 2011, 11(9):1295-1303.
65. Cipriani P., Guiducci S., Miniati I., Cinelli M., Urbani S., Marrelli A., et al. Impairment of endothelial cell differentiation from bone marrow-derived mesenchymal stem cells: new insight into the pathogenesis of systemic sclerosis. Arthritis Rheum 2007, 56:1994-2004.
66. Sun L.Y., Zhang H.Y., Feng X.B., Hou Y.Y., Lu L.W., Fan L.M. Abnormality of bone morrow-derived mesenchymal stem cells in patients with systemic lupus erythematosus. Lupus 2007, 16:121-128.
67. + regulatory T cells. Clin Exp Immunol 2009, 156(1):149-160.
68. Ryan J.M., Barry F., Murphy J.M., Mahon B.P. Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin Exp Immunol 2007, 149(2):353-363.
69. Nauta A.J., Fibbe W.E. Immunomodulatory properties of mesenchymal stromal cells. Blood 2007, 110(10):3499-3506.
70. Lanz T.V., Opitz C.A., Ho P.P., Agrawal A., Lutz C., Weller M., et al. Mouse mesenchymal stem cells suppress antigen-specific TH cell immunity independent of indoleamine 2,3-dioxygenase 1 (IDO1). Stem Cells Dev 2010, 19(5):657-668.
71. Krampera M., Cosmi L., Angeli R., Pasini A., Liotta F., Andreini A., et al. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 2006, 24(2):386-398.
72. Francois M., Romie-Mourez R., Li M., Galipeau J. Human MSC suppression correlates with cytokine induction of indoleamine 2,3-dioxygenase and bystander M2 macrophage differentiation. Mol Ther 2012, 20(1):187-195.
73. Novelli F., Bernabei P., Ozmen L., Rigamonti L., Allione A., Pestka S., et al. Switching on of the proliferation or apoptosis of activated human T lymphocytes by IFN-gamma is correlated with the differential expression of the alpha- and beta-chains of its receptor. J Immunol 1996, 157(5):1935-1943.